27 June 2024
Antibodies | Highly Viewed Papers from 2022–2023 in the Section “Antibody Discovery and Engineering”


As all of the articles published in our journal are in an open access format, you have free and unlimited access to the full texts. We welcome you to read our most highly viewed papers published in 2022 and 2023 listed below.

1. “Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries”
by Huang Aric, Wei Jin, Ahmed S. Fahad, Brooklyn K. Mussman, Grazia Paola Nicchia, Bharat Madan, Matheus Oliveira de Souza, J. Daniel Griffin, Jeffrey L. Bennett, Antonio Frigeri et al.  
Antibodies 2022, 11(2), 39; https://doi.org/10.3390/antib11020039 
Available online: https://www.mdpi.com/2073-4468/11/2/39

2. “Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics”
by F. Donelson Smith, Robert H. Pierce, Thomas Thisted and Edward H. van der Horst
Antibodies 2023, 12(3), 55; https://doi.org/10.3390/antib12030055
Available online: https://www.mdpi.com/2073-4468/12/3/55

3. “Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants”
by Robert Pejchal, Anthony B. Cooper, Michael E. Brown, Maximiliano Vásquez and Eric M. Krauland
Antibodies 2023, 12(3), 54; https://doi.org/10.3390/antib12030054
Available online: https://www.mdpi.com/2073-4468/12/3/54

4. “Exploring Parametric and Mechanistic Differences between Expi293FTM and ExpiCHO-STM Cells for Transient Antibody Production Optimization”
by Jing Zhou, Guoying Grace Yan, David Cluckey, Caryl Meade, Margaret Ruth, Rhady Sorm, Amy S. Tam, Sean Lim, Constantine Petridis, Laura Lin et al.
Antibodies 2023, 12(3), 53; https://doi.org/10.3390/antib12030053
Available online: https://www.mdpi.com/2073-4468/12/3/53

5. “Cost-Effective Protein Production in CHO Cells Following Polyethylenimine-Mediated Gene Delivery Showcased by the Production and Crystallization of Antibody Fabs”
by Klaudia Meskova, Katarina Martonova, Patricia Hrasnova, Kristina Sinska, Michaela Skrabanova, Lubica Fialova, Stefana Njemoga, Ondrej Cehlar, Olga Parmar, Petr Kolenko et al.
Antibodies 2023, 12(3), 51; https://doi.org/10.3390/antib12030051
Available online: https://www.mdpi.com/2073-4468/12/3/51

6. “Quantitation and Identification of Therapeutic Anti-CD22 Monoclonal Antibodies in a Cell-Based ELISA Method”
by Shengyu Fu and Qi Zhao
Antibodies 2022, 11(3), 53; https://doi.org/10.3390/antib11030053
Available online: https://www.mdpi.com/2073-4468/11/3/53

7. “Cutaneous Lymphoma and Antibody-Directed Therapies”
by Alvise Sernicola, Christian Ciolfi, Paola Miceli and Mauro Alaibac
Antibodies 2023, 12(1), 21; https://doi.org/10.3390/antib12010021
Available online: https://www.mdpi.com/2073-4468/12/1/21

8. “Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement”
by Zenjiro Sampei, Christine Xing’er Koo, Frannie Jiuyi Teo, Ying Xiu Toh, Taku Fukuzawa, Siok Wan Gan, Takeru Nambu, Adrian Ho, Kiyofumi Honda, Tomoyuki Igawa et al.
Antibodies 2023, 12(2), 36; https://doi.org/10.3390/antib12020036
Available online: https://www.mdpi.com/2073-4468/12/2/36

9. “Generation of Antibodies Selectively Recognizing Epitopes in a Formaldehyde-Fixed Cell-Surface Antigen Using Virus-like Particle Display and Hybridoma Technology”
by Stefanie Schatz, Lena Willnow, Monika Winkels, Jamila Franca Rosengarten, Benjamin Theek, Ian C. D. Johnston and Jörn Stitz
Antibodies 2023, 12(3), 57; https://doi.org/10.3390/antib12030057
Available online: https://www.mdpi.com/2073-4468/12/3/57

10. “Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies”
by Lotte Jacobs, Kim Stobbelaar, Annick Heykers, Paul Cos and Peter Delputte
Antibodies 2023, 12(4), 62; https://doi.org/10.3390/antib12040062
Available online: https://www.mdpi.com/2073-4468/12/4/62

Back to TopTop